ZNF611 Inhibitors
Chemical inhibitors of ZNF611 can interact with various signaling pathways and molecular mechanisms to modulate the function of this protein. Alsterpaullone, as a cyclin-dependent kinase inhibitor, can inhibit CDKs that are essential for the progression of the cell cycle. This action can prevent ZNF611 from properly regulating gene expression in a timely manner during cell division. Triptolide, which inhibits NF-kB, can impair the regulatory functions of ZNF611 in gene expression by disrupting the interaction with this transcription factor. Similarly, Chelerythrine inhibits Protein Kinase C, which may phosphorylate ZNF611 or its regulatory proteins. This can lead to functional inhibition of ZNF611 by disrupting phosphorylation events.
In addition to these, Y-27632, a selective inhibitor of ROCK, can alter cytoskeleton dynamics and cell adhesion, potentially interfering with ZNF611's localization or function. PD173074 inhibits FGFR tyrosine kinase signaling, which could disrupt pathways necessary for ZNF611's proper function. ICG-001, by antagonizing Wnt/β-catenin/TCF-mediated transcription, can disrupt ZNF611's role in gene regulation if it is dependent on Wnt signaling. SB431542, an inhibitor of the TGF-β receptor, can also disrupt signaling pathways that may regulate ZNF611. Bortezomib, as a proteasome inhibitor, can lead to the accumulation of ZNF611, potentially resulting in functional inhibition due to protein misfolding or aggregation. Rapamycin, an mTOR inhibitor, can reduce the synthesis of proteins that regulate ZNF611 activity, while LY294002, a PI3K inhibitor, can disrupt the AKT signaling pathway that may be crucial for ZNF611's transcriptional activity. Lastly, SP600125, an inhibitor of JNK, can affect ZNF611 if its activity is regulated by JNK-mediated signaling pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is an inhibitor of histone deacetylases (HDAC). As ZNF611 may interact with chromatin for transcriptional regulation, HDAC inhibition could disrupt ZNF611's function by altering the acetylation status of histones and chromatin structure. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK1/2, part of the MAPK/ERK pathway. ZNF611, being involved in transcriptional regulation, may have its activity modulated by the MAPK/ERK pathway. Inhibition by PD98059 can lead to a decrease in ZNF611's regulatory function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, which could inhibit AKT signaling. As ZNF611 is a transcription factor that could be regulated by AKT signaling, inhibition by LY294002 might lead to reduced transcriptional activity of ZNF611. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. If ZNF611 is regulated by JNK signaling, inhibition of JNK activity by SP600125 could lead to reduced functionality of ZNF611 in its capacity as a transcriptional regulator. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK, another kinase in the MAPK/ERK pathway. If ZNF611 activity is influenced by this pathway, MEK inhibition by U0126 can lead to decreased ZNF611 function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which may affect transcription factor function. As ZNF611 is involved in transcriptional regulation, inhibition of p38 MAPK by SB203580 could impair ZNF611's ability to regulate gene expression. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is an irreversible inhibitor of PI3K. If ZNF611 function is PI3K/AKT pathway-dependent, inhibition by Wortmannin could lead to a loss of ZNF611 function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. If ZNF611's function is linked to pathways regulated by mTOR, such as protein synthesis and cell growth, inhibition by Rapamycin might impede ZNF611's functional activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor. If ZNF611 is regulated through proteasomal degradation, Bortezomib's inhibition of the proteasome could lead to increased levels of ZNF611, potentially perturbing its normal function. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Thalidomide, through its anti-inflammatory effects, may inhibit NF-κB, a transcription factor that could be involved in the regulation of ZNF611. Inhibition of NF-κB by Thalidomide could result in decreased ZNF611 transcriptional activity. | ||||||